{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T20:48:47Z","timestamp":1760906927847},"reference-count":26,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2008,8,1]],"date-time":"2008-08-01T00:00:00Z","timestamp":1217548800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2008,8]]},"DOI":"10.1016\/j.ygyno.2008.04.037","type":"journal-article","created":{"date-parts":[[2008,6,7]],"date-time":"2008-06-07T08:54:13Z","timestamp":1212828853000},"page":"146-151","source":"Crossref","is-referenced-by-count":6,"title":["Treatment of recurrent or persistent platinum-refractory ovarian, fallopian tube or primary peritoneal cancer with gemcitabine and topotecan"],"prefix":"10.1016","volume":"110","author":[{"given":"Barbara A.","family":"Goff","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leona A.","family":"Holmberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Veljovich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brenda F.","family":"Kurland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2008.04.037_bib1","first-page":"1070","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer","volume":"16","author":"McGDuire","year":"1996","journal-title":"NEJM"},{"key":"10.1016\/j.ygyno.2008.04.037_bib2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0305-7372(93)90026-N","article-title":"Clinical and preclinical activity of 2\u2032, 2\u2032 diflurorodeoxy-cytidine (gemcitabine)","volume":"19","author":"Lund","year":"1993","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ygyno.2008.04.037_bib3","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1093\/jnci\/86.20.1530","article-title":"Phase II study of gemcitabine (2\u2032,2\u2032 difurorodeoxy-cytidine) in previously treated ovarian cancer patients","volume":"86","author":"Lund","year":"1994","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2008.04.037_bib4","series-title":"A phase I study of gemcitabine in previously untreated patients with advanced epithelial ovarian cancer (EOC)","volume":"vol. 15","author":"Underhill","year":"1996"},{"key":"10.1016\/j.ygyno.2008.04.037_bib5","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1093\/annonc\/4.suppl_4.S63","article-title":"New cytostatic drugs in ovarian cancer","volume":"4","author":"Hansen","year":"1993","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.ygyno.2008.04.037_bib6","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1067\/mob.2003.398","article-title":"Treatment of recurrent platinum resistant ovarian or peritoneal cancer with gemcitabine and doxorubicin: a phase I\/II trial of the Puget Sound Oncology Consortium (PSOC 1602)","volume":"188","author":"Goff","year":"2003","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ygyno.2008.04.037_bib7","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.1997.15.6.2183","article-title":"Hycamtin versus paclitaxel for the treatment of recurrent epithelial ovarian cancer","volume":"15","author":"Ten Bokkel Huinink","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2008.04.037_bib8","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.1200\/JCO.1996.14.12.3056","article-title":"Hycamtin, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study","volume":"14","author":"Cremers","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2008.04.037_bib9","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1200\/JCO.1998.16.10.3345","article-title":"Hycamtin for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treatment after prior chemotherapy containing cisplatin or carboplatin and paclitaxel","volume":"16","author":"Bookman","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2008.04.037_bib10","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1006\/gyno.2001.6435","article-title":"A dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients","volume":"83","author":"Homesley","year":"2001","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2008.04.037_bib11","first-page":"A1930","article-title":"Combined therapy with topotecan and gemcitabine in patients with inoperable or metastatic non-small cell lung cancer","volume":"18","author":"Dabrow","year":"1999","journal-title":"Proc Annual Meeting Am Soc Clin Oncol"},{"issue":"2","key":"10.1016\/j.ygyno.2008.04.037_bib12","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/1097-0142(20010715)92:2<414::AID-CNCR1337>3.0.CO;2-W","article-title":"A phase I trial of topotecan and gemcitabine administered weekly for three consecutive weeks to patients with advanced tumors","volume":"92","author":"Sun","year":"2001","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2008.04.037_bib13","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1159\/000055291","article-title":"Topotecan and gemcitabine in platinum\/paclitaxel-resistant ovarian cancer","volume":"60","author":"Greggi","year":"2001","journal-title":"Oncology"},{"issue":"3","key":"10.1016\/j.ygyno.2008.04.037_bib14","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2008.04.037_bib15","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","article-title":"The functional assessment of cancer therapy scale: development and validation of the general measure","volume":"11","author":"Cella","year":"1993","journal-title":"J Cln Oncol"},{"issue":"6","key":"10.1016\/j.ygyno.2008.04.037_bib16","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1200\/JCO.2001.19.6.1809","article-title":"Reliability and validity of the functional assessment of cancer therapy-ovarian (FACT-O)","volume":"19","author":"Basen-Enquist","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2008.04.037_bib17","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/biomet\/73.1.13","article-title":"Longitudinal data analysis using generalized linear models","volume":"7","author":"Liang","year":"1986","journal-title":"Biometrika"},{"key":"10.1016\/j.ygyno.2008.04.037_bib18","series-title":"Principles and practice of gynecologic oncology","first-page":"895","article-title":"Epithelial ovarian cancer","author":"Ozols","year":"2005"},{"issue":"29","key":"10.1016\/j.ygyno.2008.04.037_bib19","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1200\/JCO.2006.06.0913","article-title":"Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG","volume":"24","author":"Pfisterer","year":"2006","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ygyno.2008.04.037_bib20","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0090-8258(03)00011-8","article-title":"Phase II study of gemcitabine in recurrent platinum and paclitaxel-resistant ovarian cancer","volume":"88","author":"D'Agostio","year":"2003","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ygyno.2008.04.037_bib21","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0090-8258(03)00399-8","article-title":"Phase II trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer","volume":"90","author":"Markman","year":"2003","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ygyno.2008.04.037_bib22","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1046\/j.1341-8076.2003.00087.x","article-title":"A new therapeutical approach: topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy with paclitaxel and platinum","volume":"29","author":"Sehouli","year":"2003","journal-title":"J Obstet Gynaecol Res"},{"issue":"11","key":"10.1016\/j.ygyno.2008.04.037_bib23","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1093\/annonc\/mdf294","article-title":"A phase II study of topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy","volume":"13","author":"Sehouli","year":"2002","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ygyno.2008.04.037_bib24","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ygyno.2005.07.114","article-title":"A phase I trial of gemcitabine and topotecan in previously treated ovarian or peritoneal cancer: a Gynecologic Oncology Group study","volume":"100","author":"Chen","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2008.04.037_bib25","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1081\/CNV-120022363","article-title":"Combined therapy with topotecan and gemcitabine in patients with inoperable or metastatic non-small cell lung cancer","volume":"21","author":"Dabrow","year":"2003","journal-title":"Cancer Investig"},{"key":"10.1016\/j.ygyno.2008.04.037_bib26","first-page":"355","article-title":"Antagonistic effect of the combination of gemcitabine\/topotecan in ovarian cancer cells","volume":"121","author":"Distefano","year":"2000","journal-title":"Oncol Res"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825808003545?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825808003545?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,12]],"date-time":"2019-05-12T01:11:24Z","timestamp":1557623484000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825808003545"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,8]]}},"alternative-id":["S0090825808003545"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2008.04.037","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2008,8]]}}}